Introduction
The Human Immunodeficiency Virus (HIV) infects human T cells, causing a disease that progressively leads to a dramatic deterioration of the immune function. The Acquired Immunodeficiency Syndrome (AIDS) is present when CD4+ cell count is below 200 cells/mm3 or the patient has an opportunist infection, such as esophageal candidiasis or Pneumocystis pneumonia. Since life expectancy of HIV-infected individuals has increased, mostly as a result of advances in diagnosis and treatment, they are more willing to develop long-term chronic complications, some of which have been associated with vitamin D deficiency. Abnormalities in vitamin D status and metabolism might be an important concern in HIV patients, especially in those receiving Highly Active Antiretroviral Therapy (HAART). Beyond that, there seems to be evidence that antiretroviral therapy may be responsible for worsening of hypovitaminosis D [1] [2] [3] [4] .
In addition, vitamin D plays a crucial role in bone mineralization and calcium homeostasis, being essential not only to the skeletal but also to the immunologic response. It has been shown that hypovitaminosis D is more frequent among HIV-positive patients [2, 3, [5] [6] [7] . Therefore a potential role of vitamin D in HIV-infected patients has been greatly investigated.
Vitamin D supplementation has proved recently that it should be regarded as a way of slowing disease progression and preventing mortality in HIV-infected individuals. Furthermore, Vitamin D seems to play a promising and interesting role in a broad range of physiologic mechanisms, for instance, those involved in cardiovascular health [1, 8] .
In this systematic review we propose to summarize the available data on the role of vitamin D deficiency in HIV associated osteoporosis and in the modulation of the immune system in HIV-infected patients. We also aim to point out the most relevant consequences of hypovitaminosis D on the course of the infection as well as to address the potential benefits of vitamin D supplementation.
Methods
Four different databases were used to perform this search: PubMed, ISI Web of Knowledge, Scopus and Scirus. PubMed was chosen for its worldwide recognition in terms of biomedical articles. ISI Web of Knowledge and Scopus were included for their scientific international reference, as well as adequate specificity and article's high quality. Scirus was taken into account because of its wider criteria and broader coverage. We have decided to use four different databases in order to obtain the widest coverage of publications possible with trustable evidence in this topic.
We used "HIV AND vitamin D AND immune system" as our global search query in PubMed, ISI and Scopus. In Scirus we used the option "Advanced Search". By doing that we restricted our search to the articles that included "HIV AND vitamin D AND immune system" in the complete document and "HIV AND vitamin D" in the article title. We searched all databases in the April 15th, 2013. No limits were imposed at this stage in what concerns to language restriction or date of publication.
We included in our systematic review: randomized controlled trials (RCTs), observational studies, reviews (either classical or systematic) and laboratory studies. We excluded all animal research studies. In what concerns to articles' content, we included articles that assayed the immunological role of vitamin D in HIV-infected patients and excluded the ones that assessed exclusively the role of vitamin D in osteoporosis or refer to vitamin D only as a performer in tuberculosis and HIV associated tuberculosis.
In what concerns to data selection, we can divide our selection 
Stage 2

First selection
Studies excluded based on title and abstract (n = 74)
Studies retrieved for more detailed evaluation (n = 51)
Stage 3
Second selection
Studies included in the systematic review (n = 42)
Studies excluded for not fulfilling inclusion criteria (n = 21)
Studies included by hand search (n = 12) in three different and sequential stages, presented in the flowchart of Figure 1 .
The first one was the database research, in which we inserted our queries and obtained a total of 194 articles (before repetitions' elimination).
In the second stage, we performed a general selection, based on the title and abstract of all articles randomly distributed by reviewers, who examined them in teams of two elements. In addition to this, 69 repeated articles were identified and eliminated in this phase. By the end of this stage, we had a total of 51 articles.
In the third stage we made a more rigorous, specific and demanding selection based on full text reading. The previously selected articles (51) were distributed by two teams of two members. Each group performed an independent analysis and only the articles included by both reviewers (with certified agreement) became part of the final article panel. 21 more articles were excluded in this stage. Hand searches for relevant papers were performed and 12 more articles were included and searched for significant information (marked with * in the Table 1-3) .
Ultimately, all authors agreed on 42 final articles for full-text assessment. These were examined to confirm they met the established criteria and then relevant data was extracted, analyzed and combined (Table 1-3) .
Vitamin D: Physiological Roles
Vitamin D deficiency is a worldwide health problem and also an under-diagnosed condition that might compromise not only musculoskeletal health, but also affect various acute and chronic diseases [9] .
Vitamin D is an essential part of the human diet, taking part in bone mineralization and calcium homeostasis [5, 6, [10] [11] [12] [13] . Furthermore, vitamin D plays a vital role in insulin secretion, lipid metabolism, autoimmune disorders, cell proliferation and cardiovascular diseases [5] .
It is obtained by the conversion of 7-dehydrocholesterol to cholecalciferol (vitamin D3) during sunlight's skin exposure, by dietary intake and even through supplements. It can be ingested in two different forms: vitamin D2 (or ergosterol, its biological precursor) and vitamin D3, both of them hydroxylated after digestion in the liver and other tissues into 25-hydroxyvitamin D (25(OH) D3) and subsequently 1,25-dihydroxyvitamin D (1,25(OH)2D3) by CYP27B1 (1-α-hydroxylase) [6, 10] . Furthermore, some peripheral blood mononuclear cells express receptors for vitamin D (VDRs) which enables them to produce 1,25(OH)2D3 by the expression of 1-α-hydroxylase. The ligand for VDR is 1,25(OH)2D3, although this active form of vitamin D is not the best option for diagnosis and monitoring of vitamin D status. 25(OH)D3 is a better indicator of overall vitamin D status because of its expanded biological half-life and higher serum levels. Therefore the standard biomarker is 25(OH) D3 and vitamin D deficiency is present if circulating 25(OH)D3 levels are below 20 ng/mL (50 nmol/L) [6, 7, 10, 13] .
Vitamin D also plays an important role in innate immunity and antigen-specific cellular immune response. 1,25(OH)2D3 interferes with cytokine production, growth and differentiation of a variety of immune cells, functioning as a vital immunomodulatory agent in some infectious diseases such as HIV infection [6, 10, 12, 13] . On the other hand 25(OH)D3 has not shown any direct anti-mycobacterial or anti-HIV effects [14] .
An adequate vitamin D status is important not only for bone tissue but also for the global health status of all people. There is potentially a great improve in terms of health and well-being if serum levels of 25(OH)D3 are above 30 ng/mL [9, 15] . This is particularly relevant in HIV-positive individuals in whom seems to exist a significant association between vitamin D status and HIV disease's progression and survival [2, 6] .
HIV Infection, Vitamin D Deficiency and HAART
The WHO estimated an average of more than 30 million people infected with HIV in 2011 with Sub-Saharan Africa in the worst scenario [3] . The research in HIV/AIDS has led to great improvements in the prognosis of HIV-infected patients mainly after HAART [2, 3] . Since its recognition, for over than 30 years, HIV infection went from a fatal diagnosis (mostly resulting in AIDS and death) to a chronic disease [2, 3] . Investigation in this area has reduced the morbidity due to HIV/AIDS complications and has made the life expectancy of infected similar to that of uninfected individuals, however the studies' samples have been insufficient to establish broad standard protocols to monitor HIV-infected patients [2, 3, 16] .
People with HIV are increasingly reaching older age and becoming more susceptible to age-associated complications, besides that they occur earlier and at higher rates than in general population. Cardiovascular diseases, diabetes, obesity, renal impairment, cognitive dysfunction, cancer, and bone disorders have all been reported [2, 3, 5, 11] . Hypovitaminosis D is regarded as one of these complications and it has been found among HIV-infected patients at significant percentages (around 30%) [2, 3, 5, 6 ].
Vitamin D has long been known to play an important role not only in skeletal health but also in the immune system. Several studies have attempted to clarify the relationship between vitamin D and HIV disease progression: low levels of vitamin D are believed to increase the risk of progression and long term complications of HIV infection (such as those above mentioned), while increased levels have been associated to inhibition of HIV replication and lower risk of all-cause mortality [1, 5, 17, 18] .
At the same time, hypovitaminosis D is more frequent in HIVinfected patients. One suggested explanation is that persistent immune activation, through elevated levels of TNF-α, blocks the stimulatory parathyroid hormone (PTH) effect on renal 1-α-hydroxylase lowering 1,25(OH)2D3 in HIV-infected patients [2, 6, 7, 19] . This may explain why HIV-positive patients co-infected with intracellular M. avium have lower levels of vitamin D in comparison with individuals that are exclusively HIV-infected [7] . Vitamin D deficiency has also been associated with increased susceptibility to tuberculosis (both in HIV-positive or healthy subjects), a disease in which the role of either TNF-α or CD4+ cells is central [7] . Even though some studies found no correlation between vitamin D and CD4+ cell levels [1, 3, 5, 11] there are several reports of advanced HIV infections associated with decreased levels of 1,25(OH)2D3, low CD4+ cell counts and increased mortality [6, 7, 16, 19] .
Vitamin D deficiency has also higher prevalence in the following circumstances: black ethnicity (19% in White and 62% in Black patients, since naturally dark skin tone people have natural sun protection requiring 3-5 times longer solar exposure to achieve the same amount of vitamin D as a white person) , low sunlight exposure or winter months, higher body mass index, older age, feminine gender (58,1% while 24 as anticonvulsants or antiretroviral treatment (24,5% in patients without treatment and 30% in patients receiving HAART) [2, 3, [5] [6] [7] 9, 15, [19] [20] [21] . Although some data support an association between vitamin D levels and HIV infection the nature of this relationship still cannot be clarified.
As already mentioned, HAART has dramatically improved the prognosis of HIV-infected patients despite its association with several complications such as vitamin D deficiency. 25(OH)D3 concentrations inferior to 20ng/ml are more prevalent among HIVpositive individuals treated with HAART than HAART-naive or HIV-negative patients [5] . Therefore, HAART impairs vitamin D metabolism by inhibiting key enzymes such as 25-hydroxylase and 1α-hydroxylase, especially when it includes non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) [2, 5] . The impact of nucleoside reverse transcriptase inhibitors (NRTIs) has never been elucidated. Nevertheless, interactions between NRTIs and hipovitaminosis D are unlikely since NRTIs are not metabolized by cytochromes involved in vitamin D metabolism. Efavirenz (a NNRTI), on the other hand, has consistently been associated with low 25(OH)D3 concentrations as it can induce 24-hydrolyzis and inactivate vitamin D [2, 5, 11, 13, 16] . Similar but less consistent reports were found for NRTIs (like tenofovir) and for PIs. PIs, mainly ritonavir, have been demonstrated to inhibit 25-hydroxylase and 1α-hydroxylase leading to lower activation of vitamin D. At the same time PIs are effective at exerting a mild suppression on vitamin D catabolism finally leading to a diminished vitamin D net production and increasing the risk of hypovitaminosis [16, 22] .
Vitamin D, HIV and Bone Health: A Dangerous Triad?
Vitamin D deficiency has been associated with a worse disease's progression in HIV-infected individuals of all ages. In fact, there is evidence of a positive relationship between HIV infection and a higher risk of decreased bone mineral density (BMD) and osteoporosis [7] . Significant changes in bone remodeling including weight loss, decreased lean body mass and impaired functional capacity affecting OPG/KANKL/RANK system may contribute to impaired skeletal strength and increased susceptibility to fractures [23] .
Bone remodeling is somehow complex, involving a huge variety of hormones that constitute important regulators of calcium homeostasis (PTH, calcitriol, calcitonin, estrogens and androgens). These hormones interact with several local factors (for instance IL-1, IL-6, TGF, TNF, CSF), counting on OPG/RANKL/RANK system as a final osteoclastogenesis' enhancer [23] .
Furthermore, in HIV-infected patients with undetectable 1,25(OH)2D3 there might be a diminished PTH production, with normal range of calcitonin even though it cannot be explained by vitamin D depletion [19] . PTH increases calcium absorption ensuring RANKL expression in osteoblasts, crucial to induce osteoclast maturation [7] . What is already known is that in HIV infection, apart from an important T lymphocyte turnover, there is a downregulation of monocytes and macrophages' TNF receptors, leading to a down-regulation of PTH receptors and decreased cAMP response to PTH stimulation [19] .
There is still a lot to clarify about the pathophysiologic role of vitamin D deficiency in osteopenia and osteoporosis, despite both having shown high incidence in HIV-infected patients as well as an association with the length of infection, high viral load, high lactate and alkaline phosphatase levels and low bicarbonate levels. Moreover, HAART greatly affects vitamin D metabolism increasing the risk of hypovitaminosis, as mentioned before [7, 22, 23] .
Knowing that an adequate vitamin D status is essential for adequate bone mineral density, osteoprotective treatment should be started as soon as possible and vitamin D status should be measured by evaluating 25(OH)D3 and PTH levels [3, 24] .
Vitamin D and the Immune System Modulation
Vitamin D has numerous well-known metabolic functions regarding the regulation of calcium homeostasis and the skeletal system support [1, 3, 6, 25] .
In addition to this essential role regarding bone health, newer evidence suggests an important association between vitamin D and several chronic diseases, such as type 2 diabetes and cardiovascular diseases [2, 12] .
Perhaps the most significant findings are the ones that relate hypovitaminosis D to the susceptibility and response to viral infections (influenza and respiratory tract infections), particularly of enveloped virus, suggesting that vitamin D plays a major role in the regulation of immune system [2, 6, 12] . Jolliffe et al. [26] concluded a systematic review that revealed broadly consistent associations between vitamin D deficiency and susceptibility to acute respiratory infections, particularly in observational studies, with vitamin D supplementation trials demonstrating less consistent outcomes. In order to elucidate a possible association between seasonal oscillation of serum vitamin D concentrations, and the typical epidemic pattern of influenza Urashima et al. [27] designed a randomized, doubleblind, placebo-controlled clinical trial to investigated the effect of vitamin D supplements on the incidence of seasonal influenza A. The results showed a significant preventive effect against influenza A, emphasizing the important role of vitamin D in the up-regulation of the immune system. Several studies have also highlighted an association between vitamin D deficiency and tuberculosis which is partly explained by the existence of vitamin D dependent mechanisms in the antimycobacterium effector pathways responsible for mycobacterium tuberculosis elimination [14, 28] . One example is the vitamin D-dependent production of cathelicidin that follows TLR2/1-activation of monocytes infected with intracellular Mycobacterium tuberculosis [28] . This is also relevant in HIV infection since tuberculosis is the frequent major opportunistic infection and the leading cause of mortality among HIV-infected patients [29] .
Furthermore, several studies have identified an important association between HIV infection and vitamin D deficiency [1, 3, [11] [12] [13] 19, 25] .
The effects of 1,25(OH)2D3 are mediated through its interaction to the vitamin D receptor (VDR), allowing its access to the nucleus where it binds vitamin D response elements (VDRE) and regulates gene transcription [6, 7] . VDR expression is found not only in skeletal system tissues, but also in other locations such as monocytes, macrophages, dendritic cells, natural-killer cells, and T and B cells, which supports vitamin D immunomodulatory effects [7] . What also supports the immunomodulatory effects of vitamin D is the association between VDR polymorphisms and variable progression rates to AIDS and resistance to HIV infection as well as development of tuberculosis in HIV-infected individuals [29, 30] . In fact, several in vivo and in vitro studies have demonstrated these immunomodulatory properties, both in innate and adaptive immunity [2, 6, 7, 13, 17, 25] .
Vitamin D effect on Innate Immunity
1,25(OH)2D3 can act as a potent stimulator of innate antimicrobial responses [14] . Monocytes and macrophages are some of the constituents of the innate immune system in which 1,25(OH)2D3 supplementation has been found to be particularly effective [31] .
Several studies demonstrate that 1,25(OH)2D3 can improve phagocytosis and augment the respiratory burst in these cells. Moreover, it appears to enhance chemotaxis and improve maturation of monocytes [31] .
1,25(OH)2D3 improves phagocytosis:
In HIV-infected individuals the virus persists in long lived cells, including resting T cells, macrophages and dendritic cells [14, 18] . As an obligatory intracellular parasite, its survival is dependent upon its ability to evade cellular processes that prevent its growth [32] . One such process is macroautophagy, which consists of a degradation pathway for organelles and microbial pathogens in macrophages [14, 18, 32] . Macroautophagy is an essential host defense mechanism against viral and mycobacterial infections. Several studies have demonstrated that its activation in macrophages reduces the viability of HIV and M. tuberculosis [14, 18, 32, 33] . HIV evades autophagy by actively downregulating autophagy regulatory factors [32] . physiological concentrations of vitamin D inhibit the replication of HIV through the induction of autophagy in human macrophages, based on a phosphatidylinositol 3-kinase, ATG-1 and beclin-1-dependent mechanism [14, 18, 32] .
Recent research has focused on the role of Toll-like receptors (TLRs) in the macroautophagy process. In fact, cells detect intracellular pathogens through pattern recognition receptors (PRRs), which recognize signature molecules of microorganisms named pathogen-associated molecular patterns (PAMPs). TLRs are one important class of PRRs [32] . Recently it has been suggested that vitamin D plays an important role in the innate immune response via TLRs [1, 7, 32] .
Liu et al. [21] demonstrated that TLR stimulation of human macrophages: induces the enzyme (1-α-hydroxylase) that catalyzes the conversion of vitamin D to its active metabolite (1,25(OH)2D3); up-regulates the expression of the VDR; and induces relevant downstream targets of VDR, such as the cathelicidin antimicrobial peptide (CAMP). Other studies highlighted the action of vitamin D as a key link between TLR activation and several antibacterial responses in HIV infected patients, pointing out the ability of Vitamin D in affecting disease progression and mortality among HIV-infected patients [1, 32] . TLR8 is an important toll-like receptor with an interesting distribution: monocytes, macrophages, myeloid dendritic cells and regulatory T cells [32] . TLR8 recognizes singlestranded RNA (ssRNA) and, once activated, leads to the induction of an antiviral effector cascade, which is responsible for the induction of autophagy. Recent research has elucidated that TLR8 agonists inhibit HIV replication in macrophages through a vitamin D and CAMPdependent process [32] .
Some anti-microbial peptides associated with TLRs (for instance, CAMP LL-37 and human beta defensin 2) have demonstrated antiviral effects, and their expression is affected by vitamin D [6] . Expression of these antimicrobial peptides is also up-regulated in macrophages stimulated by 1,25(OH)2D3. Consequently, individuals with vitamin D deficiency may have impaired autophagy and oxidative burst, resulting in an increased incidence or even more severe opportunistic infections [2, 6, 14, 32] .
As previously mentioned, CAMP LL-37 enhances innate immunity through an increased autophagy in macrophages and is particularly important in the protection against pathogens such as Mycobacterium tuberculosis [7, 32] . Furthermore, LL-37 has broad antimicrobial activity against bacteria, fungi and certain viruses. It also exerts chemotactic, immunomodulatory and angiogenic effects and decreases serum levels of pro-inflammatory cytokines [7] . These findings suggest that the induction of autophagy has the potential to be useful in the prevention and treatment of HIV-1 infection and related opportunistic infections [14, 18] .
1,25(OH)2D3 induces monocytes maturation:
Macrophages play a critical role in protecting against intracellular pathogens. In fact, many of the opportunistic infections seen in HIV-infected patients are due to intracellular microorganisms, such as Mycobacterium tuberculosis, suggesting an impairment in the macrophage function. This raises an important question: could this impairment be due to a defect in maturation of monocytes in HIV-infected patients? [34] .
1,25(OH)2D3 has been shown to induce maturation of normal monocytes to macrophages, as well as monocytes differentiation of bone marrow precursors [34, 35] . Additionally, some in vitro studies have demonstrated that 1,25(OH)2D3 plays an important role in regulating macrophage function in HIV-infected individuals since it is able to modulate HIV infection in human macrophages, via the induction of cellular differentiation [36] .
One important aspect of latently infected macrophages in HIV infection relates with their ability to function as a virus reservoir and to produce infectious virus [37] . Therefore it is possible that cellular differentiation plays a role in increasing HIV susceptibility and/or progression through the expansion of this viral reservoir [37] . Goletti et al. [37] verified that vitamin D3 monocytes stimulation induced cellular differentiation but did not induce HIV expression, demonstrating dissociation between cellular differentiation and viral expression. Furthermore, it was observed by this same study that vitamin D effect on viral expression was associated with the cytokine environment, since vitamin D3 enhanced HIV expression in the presence of TNF-a but inhibited viral expression in the presence of gamma interferon (IFN-γ), IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF).
Adaptive Immunity
Some studies had described important effects of 1,25(OH)2D3 in adaptive immunity, particularly in T cell activation and phenotype modulation. 1,25(OH)2D3 also seems to play an important role in antigen-presenting cells' function and IL-10 production [2, 7, 10] .
Treg cells have particular relevance as they are involved on inactivation and inhibition of T cell proliferation by shifting from a Th1 to a Th2 response. Recently, Treg cells have been subject of great interest not only in HIV infection, but also in transplants, autoimmune diseases and immune cancer. Treg cells may represent an interesting opportunity for the control of HIV infection, as they suppress T cell expansion limiting viral replication [2, 25] .
The progression of HIV infection is associated with a decrease in the number and function of Treg and CD4+ cells. In addition to this, recent studies have demonstrated an association between HIV infection and 1,25(OH)2D3 deficiency. The relationship between decreased levels of vitamin D and equally decreased Treg cells numbers has already been demonstrated, but the opposite was not verified yet [6, 7, 25] . Recent studies have showed that the increase in viral load is associated with Treg cells accumulation in secondary lymphoid tissues, explaining the decrease in plasmatic Treg cells during the process of HIV infection [25] .
Moreover, Vitamin D affects the maturation and differentiation of dendritic cells, being also able to induce a tolerogenic phenotype [7, 10] .
It has also been proved in vitro that 1,25(OH)2D3 reduces B cell proliferation, plasmatic differentiation and immunoglobulin production. This can be important for the reduction of inflammation, tissue destruction, and immune response to opportunistic infections in individuals with adequate levels of vitamin D, attenuating its severity and mortality [11] .
Vitamin D Supplementation and HIV Infection
Several studies had reported that vitamin D deficiency negatively interferes with the progression and mortality of HIV infection, and so adequate levels of vitamin D may be important for the global health status of HIV-infected children and adults [2, 7, 19, 25] .
Besides the overall benefit of vitamin D sufficiency status, there are some particular subsets of the HIV-infected population that may have specific advantages with vitamin D supplementation. It has been suggested that adequate levels of vitamin D are beneficial for pregnant women, even without HIV infection, due to its role in the development of the fetal immune function [17, 38] of Medicine (IOM) recommends a vitamin D intake of 400-600 IU/day during pregnancy for all women whereas the Endocrine Society suggests an intake of 1,500-2,000 IU/day [39] [40] [41] . However, results of two studies support that, in comparison with the groups receiving supplements of 400 and 2000 IU/day, a daily vitamin D supplementation of 4000 IU was not only considered safe (neither hypercalcemia or hypercalciuria were observed) but it was also associated with a lower risk of hypovitaminosis D and comorbidities during pregnancy [39, 41] . 884 HIV-infected pregnant women who received daily doses of a vitamin supplement (which had not included vitamin D) in Tanzania were followed in an observational analysis to assess the association between vitamin D status and pregnancy outcomes [17] . Low maternal vitamin D level at 12-27 weeks' gestation was not associated with outcomes as low birth weight, preterm birth or small for gestational age. Nevertheless, an insufficient maternal vitamin D level was significantly associated with an increased risk of mother-to-child transmission at 6 weeks of age and through breast-feeding and infant mortality during follow-up [17] . One of the limitations of this study, however, is related to the assay that was used to determine the vitamin D status which does not give an accurate measure [17] .
Another situation was studied by Stein et al who observed that the lack of nutritional supplementation was associated with vitamin D deficiency in HIV-infected postmenopausal women [16] . In spite of this, it is important to refer that this study has some limitations such as small sample size, the cross-sectional design and a potential selection bias (subjects were women living in New York) [16] .
Due to all the potential benefits of vitamin D supplementation, some researchers have attempted to explore the effects of external administration of cholecalciferol in vitamin D deficient HIV-infected adults [25] . One of these studies aimed to investigate the effects of cholecalciferol supplementation in vitamin D levels, BMD and insulin sensitivity (in general population, low levels of 25(OH)D3 are associated with increased risk of type 2 diabetes) [25, 42] . Patients were treated with 2000 IU cholecalciferol/day for 14 weeks after which treatment was continued with 1000 IU/day until 48 weeks. After 24 weeks, an increase of 25(OH)D3 and 1,25(OH)2D3 levels was registered, as well as a decrease in PTH and insulin sensitivity. Nevertheless, after 48 weeks, the levels of 25(OH)D3 were the only with significant changes. Neither CD4+ cell number nor BMD were modified [25] . With a small sample size (20 vitamin D deficient HIV-1-infected patients), the results of this explorative study need to be confirmed in larger clinical trials [25] .
Another study in the same population aimed to explore the effects of cholecalciferol supplementation on circulating CD4+ CD25 high Treg numbers, given their important role in immunity and tolerance [25] . Under the same supplementation regimen aforementioned, subjects showed a similar pattern of changes, with regard to 25(OH) D3, 1,25(OH)2D3 and PTH levels [25] . The absolute numbers of circulating CD4+ CD25 high Treg, as well as the percentage of CD4+ CD25 high Treg in the CD4+ cell subset, decreased with the administration of 2000 IU cholecalciferol/day [25] . However, with a lower dose of cholecalciferol (1000 IU/day), those values were again at baseline. Both studies indicate that, in HIV-infected patients the cholecalciferol supplementation appears to have a dose dependent effect because both Treg cells numbers and 1,25(OH)2D3 levels returned to baseline when the cholecalciferol's dosage was decreased (1000 IU/day) [25] . It is suggested that a supplementation of >2000 IU cholecalciferol per day would enable the achievement of the optimal levels of vitamin D in HIV-infected patients [25] . However, the development of insulin resistance may be an eventual side effect [25] . Besides the small sample size, another limitation of this study concerns the phenotypic analysis which does not allow an accurate understanding of the influence of vitamin D supplementation on the function of Treg or on their distribution [25] .
While larger studies and randomized clinical trials should be developed to define its optimal doses, vitamin D supplementation seems to be a promising, simple and economical way of improving bone health and immune function in HIV-infected individuals [7, 12, 17, 25] .
Conclusion
Recently, mortality in HIV-infected individuals has dramatically decreased as a result of all the investment made in diagnosis and management of HIV infection [2] . This is, partly, a consequence of the implementation of successful interventions, from which HAART is a main reference.
Despite all the benefits of an anti-retroviral therapy (ART), some evidence suggests that HIV-infected subjects treated with HAART have higher risk of vitamin D deficiency and also cancer, cardiovascular disease, diabetes and other immunological diseases [5] . Not only vitamin D deficiency is highly prevalent in HIV-positive patients, but also NNRTI therapy further decreases 25(OH)D3 serum levels [3, 5] . The importance of an adequate level of vitamin D and its beneficial effect on several chronic diseases, and not just bone health, are explored in several studies, most of which observational [2, 25] . Due to the high frequency of hypovitaminosis D in HIV-infected individuals, possible implications of such status in HIV infection and in the disease progression are a subject of extensive research [1, 2, 19, 30] .
There are still aspects that need to be clarified in larger clinical randomized controlled trials such as the benefits of vitamin D supplementation for nonskeletal health and acute and chronic diseases. However, it seems that vitamin D supplementation could be a simple and low-cost way of improving health and postponing the initiation of ART in HIV-infected patients [1, 3, 9, 25] .
